肝移植术后乙型肝炎病毒再激活的分子机制研究进展

杨健; 谢炎; 田大治; 张骊; 张洋铭; 蒋文涛

doi:10.3969/j.issn.1674-7445.2020.02.019

肝移植术后乙型肝炎病毒再激活的分子机制研究进展

doi: 10.3969/j.issn.1674-7445.2020.02.019

300192 天津市第一中心医院器官移植中心器官移植科

基金项目:

国家自然科学基金面上项目 81870444

天津市科委慢性病防治科技重大专项 17ZXMFSY00040

天津市第一中心医院春蕾计划 CL201801

天津市自然科学基金 19JCQNJC10300

详细信息

作者简介:
杨健，男，1987年生，博士，医师，研究方向为器官移植，Email：yangjian0628@126.com

通讯作者:
蒋文涛，男，1974年生，博士，主任医师，研究方向为器官移植，Email：447660280@qq.com

中图分类号: R617, R373.21
计量
- 文章访问数: 126
- HTML全文浏览量: 16
- PDF下载量: 11
- 被引次数: 0
出版历程
- 收稿日期: 2019-12-20
- 网络出版日期: 2021-01-19
- 刊出日期: 2020-03-15

Research progress on molecular mechanism of hepatitis B virus reactivation after liver transplantation

Organ Transplantation Center, Department of Organ Transplantation, Tianjin First Central Hospital, Tianjin 300192, China

More Information

Corresponding author: Jiang Wentao, Email: 447660280@qq.com

摘要

摘要: 肝移植是治疗乙型病毒性肝炎（乙肝）相关性肝衰竭、肝硬化和肝细胞癌（肝癌）的最有效方法。然而，肝移植术后乙型肝炎病毒（HBV）再激活不利于移植肝功能恢复且导致预后不良，其防治问题是当前内、外科医师研究的焦点。目前的病毒抑制策略不能完全根除HBV，也不能完全预防HBV在未来复发感染。本文旨在探讨肝移植术后HBV再激活的分子机制，以期更有效预防肝移植术后乙肝复发。
- 肝移植 /
- 乙型肝炎病毒 /
- 超螺旋共价闭环DNA (cccDNA) /
- 基因整合 /
- 肝外复制 /
- 乙型病毒性肝炎复发 /
- 丁型肝炎病毒 /
- 基因型
Abstract: Liver transplantation is the most effective method for hepatitis B-related liver failure, liver cirrhosis and hepatocellular carcinoma. However, the reactivation of hepatitis B virus (HBV) after liver transplantation is not conducive to the recovery of liver function and leads to poor clinical prognosis. The prevention and treatment of HBV reactivation is currently the focus of research by physicians and surgeons. The current viral suppression strategies can not completely eradicate HBV nor completely prevent the recurrence of HBV infection in the future. This article aims to explore the molecular mechanism of HBV reactivation after liver transplantation, in order to more effectively prevent the recurrence of hepatitis B after liver transplantation.
- Liver transplantation /
- Hepatitis B virus /
- Covalently closed circular DNA (cccDNA) /
- Gene integration /
- Extrahepatic replication /
- Hepatitis B recurrence /
- Hepatitis D virus /
- Genotype

HTML全文

参考文献(43)

[1]	STOCKDALE AJ, MITAMBO C, EVERETT D, et al. Epidemiology of hepatitis B, C and D in Malawi: systematic review[J]. BMC Infect Dis, 2018, 18(1):516. DOI: 10.1186/s12879-018-3428-7.
[2]	HIBI T, SUGAWARA Y. Locoregional therapy as a bridge to liver transplantation for hepatocellular carcinoma within Milan criteria: from a transplant oncology viewpoint[J]. Hepatobiliary Surg Nutr, 2018, 7(2):134-135. DOI: 10.21037/hbsn.2018.01.07.
[3]	BODZIN AS, BAKER TB. Liver transplantation today: where we are now and where we are going[J]. Liver Transpl, 2018, 24(10):1470-1475. DOI: 10.1002/lt.25320.
[4]	TAHARA H, OHDAN H. HBV reactivation after liver transplantation and the management strategies[J]. Nihon Rinsho, 2015, 73 (Suppl 9):550-554. http://cn.bing.com/academic/profile?id=d402e9ce2f5365994b57558ba5a85f2e&encoded=0&v=paper_preview&mkt=zh-cn
[5]	SORIANO V, BARREIRO P, BENITEZ L, et al. New antivirals for the treatment of chronic hepatitis B[J]. Expert Opin Investig Drugs, 2017, 26(7):843-851. DOI: 10.1080/13543784.2017.1333105.
[6]	MAIER M, LIEBERT UG, WITTEKIND C, et al. Clinical relevance of minimal residual viremia during long-term therapy with nucleos(t)ide analogues in patients with chronic hepatitis B[J]. PLoS One, 2013, 8(6):e67481. DOI: 10.1371/journal.pone.0067481.
[7]	LI X, ZHAO J, YUAN Q, et al. Detection of HBV covalently closed circular DNA[J]. Viruses, 2017, 9(6):139. DOI: 10.3390/v9060139.
[8]	KASRAIANFARD A, WATT KD, LINDBERG L, et al. HBIG remains significant in the era of new potent nucleoside analogues for prophylaxis against hepatitis B recurrence after liver transplantation[J]. Int Rev Immunol, 2016, 35(4):312-324. http://www.ncbi.nlm.nih.gov/pubmed/24911598
[9]	CHAUHAN R, LINGALA S, GADIPARTHI C, et al. Reactivation of hepatitis B after liver transplantation: current knowledge, molecular mechanisms and implications in management[J]. World J Hepatol, 2018, 10(3):352-370. DOI: 10.4254/wjh.v10.i3.352.
[10]	LIU S, ZHOU B, VALDES JD, et al. Serum hepatitis B virus RNA: a new potential biomarker for chronic hepatitis B virus infection[J]. Hepatology, 2019, 69(4):1816-1827. DOI: 10.1002/hep.30325.
[11]	WONG DK, SETO WK, FUNG J, et al. Reduction of hepatitis B surface antigen and covalently closed circular DNA by nucleos(t)ide analogues of different potency[J]. Clin Gastroenterol Hepatol, 2013, 11(8):1004-1010. DOI: 10.1016/j.cgh.2013.01.026.
[12]	PAPATHEODORIDIS GV, MANOLAKOPOULOS S, TOULOUMI G, et al. Virological suppression does not prevent the development of hepatocellular carcinoma in HBeAg-negative chronic hepatitis B patients with cirrhosis receiving oral antiviral(s) starting with lamivudine monotherapy: results of the nationwide HEPNET. Greece cohort study[J]. Gut, 2011, 60(8):1109-1116. DOI: 10.1136/gut.2010.221846.
[13]	GENTILE G, ANDREONI M, ANTONELLI G, et al. Screening, monitoring, prevention, prophylaxis and therapy for hepatitis B virus reactivation in patients with haematologic malignancies and patients who underwent haematologic stem cell transplantation: a systematic review[J]. Clin Microbiol Infect, 2017, 23(12):916-923. DOI: 10.1016/j.cmi.2017.06.024.
[14]	LIN CL, KAO JH. Natural history of acute and chronic hepatitis B: the role of HBV genotypes and mutants[J]. Best Pract Res Clin Gastroenterol, 2017, 31(3):249-255. DOI: 10.1016/j.bpg.2017.04.010.
[15]	ITO K, YONEDA M, SAKAMOTO K, et al. Virological and clinical characteristics of hepatitis B virus genotype A[J]. J Gastroenterol, 2018, 53(1):18-26. DOI: 10.1007/s00535-017-1367-5.
[16]	UZ-ZAMAN MH, RAHMAN A, YASMIN M. Epidemiology of hepatitis B virus infection in Bangladesh: prevalence among general population, risk groups and genotype distribution[J]. Genes (Basel), 2018, 9(11):541. DOI: 10.3390/genes9110541.
[17]	YEH CT, LIANG KH, CHANG ML, et al. Phenotypic and genotypic shifts in hepatitis B virus in treatment-naive patients, Taiwan, 2008-2012[J]. Emerg Infect Dis, 2017, 23(5):820-821. DOI: 10.3201/eid2305.161894.
[18]	HASSEMER M, FINKERNAGEL M, PEIFFER KH, et al. Comparative characterization of hepatitis B virus surface antigen derived from different hepatitis B virus genotypes[J]. Virology, 2017, 502:1-12. DOI: 10.1016/j.virol.2016.12.003.
[19]	LI X, LIU Y, XIN S, et al. Comparison of detection rate and mutational pattern of drug-resistant mutations between a large cohort of genotype B and genotype C hepatitis B virus-infected patients in north China[J]. Microb Drug Resist, 2017, 23(4):516-522. DOI: 10.1089/mdr.2016.0093.
[20]	GOYAL A, MURRAY JM. Roadmap to control HBV and HDV epidemics in China[J]. J Theor Biol, 2017, 423:41-52. DOI: 10.1016/j.jtbi.2017.04.007.
[21]	COUTO I, VICTORIA M, VELOSO VG, et al. Prevalence and predictors for compensated advanced chronic liver disease (c-ACLD) in patients with chronic hepatitis delta virus (HDV) infection[J]. PLoS One, 2017, 12(3):e0174453. DOI: 10.1371/journal.pone.0174453.
[22]	STROFFOLINI T, SAGNELLI E, SAGNELLI C, et al. Hepatitis delta infection in Italian patients: towards the end of the story?[J]. Infection, 2017, 45(3):277-281. DOI: 10.1007/s15010-016-0956-1.
[23]	RICCO G, POPA DC, CAVALLONE D, et al. Quantification of serum markers of hepatitis B (HBV) and Delta virus (HDV) infections in patients with chronic HDV infection[J]. J Viral Hepat, 2018, 25(8):911-919. DOI: 10.1111/jvh.12895.
[24]	LUPIA T, CORCIONE S, BOGLIONE L, et al. Visceral leishmaniasis in a patient with active HBV/HDV co-infection[J]. J Infect Public Health, 2020, 13(2):306-308. DOI: 10.1016/j.jiph.2019.07.026.
[25]	PEREZ-VARGAS J, AMIRACHE F, BOSON B, et al. Enveloped viruses distinct from HBV induce dissemination of hepatitis D virus in vivo[J]. Nat Commun, 2019, 10(1):2098. DOI: 10.1038/s41467-019-10117-z.
[26]	YURDAYDIN C, ABBAS Z, BUTI M, et al. Treating chronic hepatitis delta: the need for surrogate markers of treatment efficacy[J]. J Hepatol, 2019, 70(5):1008-1015. DOI: 10.1016/j.jhep.2018.12.022.
[27]	HÖNER ZU SIEDERDISSEN C, CORNBERG M. Management of HBV and HBV/HDV-associated liver cirrhosis[J]. Visc Med, 2016, 32(2):86-94. DOI: 10.1159/ 000445518.
[28]	JIANG Z, FENG X, ZHANG W, et al. Recipient cytotoxic T lymphocyte antigen-4 +49 G/G genotype is associated with reduced incidence of hepatitis B virus recurrence after liver transplantation among Chinese patients[J]. Liver Int, 2007, 27(9):1202-1208. http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=470f553a1726f1d52eb519137ec169e6
[29]	XIA C, LU M, ZHANG Z, et al. TLRs antiviral effect on hepatitis B virus in HepG2 cells[J]. J Appl Microbiol, 2008, 105(5):1720-1727. DOI: 10.1111/j.1365-2672.2008. 03896.x.
[30]	JIANG M, BROERING R, TRIPPLER M, et al. Toll-like receptor-mediated immune responses are attenuated in the presence of high levels of hepatitis B virus surface antigen[J]. J Viral Hepat, 2014, 21(12):860-872. DOI: 10.1111/jvh.12216.
[31]	TESTONI B, LEVRERO M, ZOULIM F. Challenges to a cure for HBV infection[J]. Semin Liver Dis, 2017, 37(3):231-242. DOI: 10.1055/s-0037-1606212.
[32]	SUNG WK, ZHENG H, LI S, et al. Genome-wide survey of recurrent HBV integration in hepatocellular carcinoma[J]. Nat Genet, 2012, 44(7):765-769. DOI: 10.1038/ng.2295.
[33]	CHAUHAN R, CHURCHILL ND, MULROONEY-COUSINS PM, et al. Initial sites of hepadnavirus integration into host genome in human hepatocytes and in the woodchuck model of hepatitis B-associated hepatocellular carcinoma[J]. Oncogenesis, 2017, 6(4):e317. DOI: 10.1038/oncsis.2017.22.
[34]	COUGOT D, NEUVEUT C, BUENDIA MA. HBV induced carcinogenesis[J]. J Clin Virol, 2005, 34 (Suppl 1):S75-S78. http://d.old.wanfangdata.com.cn/Periodical/gxykdx200102001
[35]	MARUSAWA H, UEMOTO S, HIJIKATA M, et al. Latent hepatitis B virus infection in healthy individuals with antibodies to hepatitis B core antigen[J]. Hepatology, 2000, 31(2):488-495. doi: 10.1002/hep.510310232
[36]	XUAN SY, SUN Y, ZHANG J. The influence to the function of cellular immunity after being infected by HBV in the PBMC in chronic hepatitis B[J]. Chin J Epidemiol, 1997, 18(2):80-82. http://cn.bing.com/academic/profile?id=46a636ad47400a355ec33ff5657947b0&encoded=0&v=paper_preview&mkt=zh-cn
[37]	COFFIN CS, MULROONEY-COUSINS PM, PETERS MG, et al. Molecular characterization of intrahepatic and extrahepatic hepatitis B virus (HBV) reservoirs in patients on suppressive antiviral therapy[J]. J Viral Hepat, 2011, 18(6):415-423. DOI: 10.1111/j.1365-2893.2010.01321.x.
[38]	BUDZINSKA MA, SHACKEL NA, URBAN S, et al. Cellular genomic sites of hepatitis B virus DNA integration[J]. Genes (Basel), 2018, 9(7):365. DOI: 10.3390/genes9070365.
[39]	GATTA A, GIANNINI C, LAMPERTICO P, et al. Hepatotropic viruses: new insights in pathogenesis and treatment[J]. Clin Exp Rheumatol, 2008, 26(1 Suppl 48): S33-S38. http://cn.bing.com/academic/profile?id=b2074f0be7c58145999b2f850f792fd2&encoded=0&v=paper_preview&mkt=zh-cn
[40]	VLACHOGIANNAKOS J, PAPATHEODORIDIS GV. Hepatitis B: who and when to treat?[J]. Liver Int, 2018, 38 (Suppl 1):71-78. DOI: 10.1111/liv.13631.
[41]	HUANG W, ZHAO F, HUANG Y, et al. Rapamycin enhances HBV production by inducing cellular autophagy[J]. Hepat Mon, 2014, 14(10):e20719. DOI: 10.5812/hepatmon.20719.
[42]	BRENNAN DC, AGUADO JM, POTENA L, et al. Effect of maintenance immunosuppressive drugs on virus pathobiology: evidence and potential mechanisms[J]. Rev Med Virol, 2013, 23(2):97-125. DOI: 10.1002/rmv.1733.
[43]	于乐成, 范晔, 李平等.与直接抗病毒药物应用相关的HCV/HBV双重感染的特点及其诊治管理[J].临床肝胆病杂志, 2018, 34(2):238-241. DOI: 10.3969/j.issn.1001-5256.2018.02.004. YU LC, FAN Y, LI P, et al. Features and management of patients with hepatitis C virus/hepatitis B virus dual infection associated with the application of direct-acting antiviral agents[J]. J Clin Hepatol, 2018, 34(2):238-241. DOI: 10.3969/j.issn.1001-5256.2018.02.004.